| Honey E Sward, MD | |
|
301 Hospital Dr, Pediatrics, Glen Burnie, MD 21061-5803 | |
| (410) 787-4000 | |
| Not Available |
| Full Name | Honey E Sward |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 301 Hospital Dr, Glen Burnie, Maryland |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205964525 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | D67417 (Maryland) | Primary |
| 208M00000X | Hospitalist | D67417 (Maryland) | Secondary |
| Entity Name | St Paul Place Specialists Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871549196 PECOS PAC ID: 7719882943 Enrollment ID: O20031202000084 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the Board of Appeals of the European Patent Office (EPO) has ruled that claims of the Kreutzer-Limmer '945 (EP 1214945) patent meet needed requirements under European patent law. The '945 patent comprises broad claims covering the length and certain structural requirements for siRNAs that are important for advancement of RNAi therapeutics.
It took clinical trial experts Synexus, just ten months to carry out 52,000 DEXA scans and randomise over 2,700 patients across twelve of their UK, European and African dedicated research centres.
In an editorial entitled "The Unmet Promise of a Miracle Drug for Alzheimer's Disease: Implications for Practice, Policy, and Research," Malaz Boustani, MD, MPH, a Regenstrief Institute research scientist and the founding director of the Indiana University Center for Health Innovation and Implementation Science, and co-authors Philip D. Sloane, MD, MPH and Sheryl Zimmerman, PhD, of the University of North Carolina at Chapel Hill, lament the unmet promise of a miracle drug for Alzheimer disease but are heartened by what they see as encouraging improvements in care for a growing population of older adults, many with dementia.
In a post in USAID's "IMPACTblog," Ariel Pablos-Mendez, assistant administrator for global health at USAID, provides an overview of India's "Call to Action Summit for Child Survival and Development," which took place last week, writing, "Led by India's Ministry of Health and Family Welfare, the Summit called for an accelerated response to decrease child mortality across the country."
› Verified 5 days ago
| Entity Name | University Of Maryland Community Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477530624 PECOS PAC ID: 3678472214 Enrollment ID: O20040102000687 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the Board of Appeals of the European Patent Office (EPO) has ruled that claims of the Kreutzer-Limmer '945 (EP 1214945) patent meet needed requirements under European patent law. The '945 patent comprises broad claims covering the length and certain structural requirements for siRNAs that are important for advancement of RNAi therapeutics.
It took clinical trial experts Synexus, just ten months to carry out 52,000 DEXA scans and randomise over 2,700 patients across twelve of their UK, European and African dedicated research centres.
In an editorial entitled "The Unmet Promise of a Miracle Drug for Alzheimer's Disease: Implications for Practice, Policy, and Research," Malaz Boustani, MD, MPH, a Regenstrief Institute research scientist and the founding director of the Indiana University Center for Health Innovation and Implementation Science, and co-authors Philip D. Sloane, MD, MPH and Sheryl Zimmerman, PhD, of the University of North Carolina at Chapel Hill, lament the unmet promise of a miracle drug for Alzheimer disease but are heartened by what they see as encouraging improvements in care for a growing population of older adults, many with dementia.
In a post in USAID's "IMPACTblog," Ariel Pablos-Mendez, assistant administrator for global health at USAID, provides an overview of India's "Call to Action Summit for Child Survival and Development," which took place last week, writing, "Led by India's Ministry of Health and Family Welfare, the Summit called for an accelerated response to decrease child mortality across the country."
› Verified 5 days ago
| Entity Name | Baltimore Washington Emergency Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215983853 PECOS PAC ID: 3577451103 Enrollment ID: O20040305001004 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the Board of Appeals of the European Patent Office (EPO) has ruled that claims of the Kreutzer-Limmer '945 (EP 1214945) patent meet needed requirements under European patent law. The '945 patent comprises broad claims covering the length and certain structural requirements for siRNAs that are important for advancement of RNAi therapeutics.
It took clinical trial experts Synexus, just ten months to carry out 52,000 DEXA scans and randomise over 2,700 patients across twelve of their UK, European and African dedicated research centres.
In an editorial entitled "The Unmet Promise of a Miracle Drug for Alzheimer's Disease: Implications for Practice, Policy, and Research," Malaz Boustani, MD, MPH, a Regenstrief Institute research scientist and the founding director of the Indiana University Center for Health Innovation and Implementation Science, and co-authors Philip D. Sloane, MD, MPH and Sheryl Zimmerman, PhD, of the University of North Carolina at Chapel Hill, lament the unmet promise of a miracle drug for Alzheimer disease but are heartened by what they see as encouraging improvements in care for a growing population of older adults, many with dementia.
In a post in USAID's "IMPACTblog," Ariel Pablos-Mendez, assistant administrator for global health at USAID, provides an overview of India's "Call to Action Summit for Child Survival and Development," which took place last week, writing, "Led by India's Ministry of Health and Family Welfare, the Summit called for an accelerated response to decrease child mortality across the country."
› Verified 5 days ago
| Entity Name | Emergency Physicians Spps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760885958 PECOS PAC ID: 0648594036 Enrollment ID: O20150113000263 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the Board of Appeals of the European Patent Office (EPO) has ruled that claims of the Kreutzer-Limmer '945 (EP 1214945) patent meet needed requirements under European patent law. The '945 patent comprises broad claims covering the length and certain structural requirements for siRNAs that are important for advancement of RNAi therapeutics.
It took clinical trial experts Synexus, just ten months to carry out 52,000 DEXA scans and randomise over 2,700 patients across twelve of their UK, European and African dedicated research centres.
In an editorial entitled "The Unmet Promise of a Miracle Drug for Alzheimer's Disease: Implications for Practice, Policy, and Research," Malaz Boustani, MD, MPH, a Regenstrief Institute research scientist and the founding director of the Indiana University Center for Health Innovation and Implementation Science, and co-authors Philip D. Sloane, MD, MPH and Sheryl Zimmerman, PhD, of the University of North Carolina at Chapel Hill, lament the unmet promise of a miracle drug for Alzheimer disease but are heartened by what they see as encouraging improvements in care for a growing population of older adults, many with dementia.
In a post in USAID's "IMPACTblog," Ariel Pablos-Mendez, assistant administrator for global health at USAID, provides an overview of India's "Call to Action Summit for Child Survival and Development," which took place last week, writing, "Led by India's Ministry of Health and Family Welfare, the Summit called for an accelerated response to decrease child mortality across the country."
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Honey E Sward, MD 301 Hospital Dr, Pediatrics, Glen Burnie, MD 21061-5803 Ph: (410) 787-4000 | Honey E Sward, MD 301 Hospital Dr, Pediatrics, Glen Burnie, MD 21061-5803 Ph: (410) 787-4000 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the Board of Appeals of the European Patent Office (EPO) has ruled that claims of the Kreutzer-Limmer '945 (EP 1214945) patent meet needed requirements under European patent law. The '945 patent comprises broad claims covering the length and certain structural requirements for siRNAs that are important for advancement of RNAi therapeutics.
It took clinical trial experts Synexus, just ten months to carry out 52,000 DEXA scans and randomise over 2,700 patients across twelve of their UK, European and African dedicated research centres.
In an editorial entitled "The Unmet Promise of a Miracle Drug for Alzheimer's Disease: Implications for Practice, Policy, and Research," Malaz Boustani, MD, MPH, a Regenstrief Institute research scientist and the founding director of the Indiana University Center for Health Innovation and Implementation Science, and co-authors Philip D. Sloane, MD, MPH and Sheryl Zimmerman, PhD, of the University of North Carolina at Chapel Hill, lament the unmet promise of a miracle drug for Alzheimer disease but are heartened by what they see as encouraging improvements in care for a growing population of older adults, many with dementia.
In a post in USAID's "IMPACTblog," Ariel Pablos-Mendez, assistant administrator for global health at USAID, provides an overview of India's "Call to Action Summit for Child Survival and Development," which took place last week, writing, "Led by India's Ministry of Health and Family Welfare, the Summit called for an accelerated response to decrease child mortality across the country."
› Verified 5 days ago
Dr. Stephen Joseph Hittman, D.O. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 301 Hospital Dr, Glen Burnie, MD 21061 Phone: 410-787-4000 Fax: 410-595-1914 | |
Astrid Rivera Rodriguez, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6622b Ritchie Hwy Arundel Plaza,, Glen Burnie, MD 21061 Phone: 443-912-5437 | |
Jessica S Kosut, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 301 Hospital Dr, Glen Burnie, MD 21061 Phone: 410-787-4565 Fax: 410-766-7602 | |
Sushma Bhasin, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 331 Oak Manor Dr, Glen Burnie, MD 21061 Phone: 410-768-0700 Fax: 410-768-1143 | |
Dr. Padma M Lala, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1410 Crain Hwy N, Ste 3a, Glen Burnie, MD 21061 Phone: 410-766-7800 Fax: 410-766-7855 | |
Dr. Harini Sankhavaram Prasanna, M.D Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 325 Hospital Dr, 204, Glen Burnie, MD 21061 Phone: 410-768-8525 Fax: 410-768-9757 | |
D R Fitzgerald, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 301 Hospital Dr, Glen Burnie, MD 21061 Phone: 410-787-4565 Fax: 410-766-7602 |